Wolff J M, Ittel T, Borchers H, Brauers A, Jakse G
Department of Urology, RWTH Aachen, Germany.
Urol Int. 1998 Oct;61(1):12-6. doi: 10.1159/000030276.
To study the efficacy of prostate-specific antigen (PSA) and skeletal alkaline phosphatase (SAP) as staging markers in discriminating patients with cancer of the prostate (CaP) with (M+) and without bone metastases (M0).
73 patients with untreated CaP entered the study. After staging the patients were divided into 3 groups: group I, patients with CaP and bone metastases (n = 21); group II, patients with locally advanced CaP without bone metastases (n = 26), and group III, patients with clinically localized CaP without bone metastases (n = 26).
None of the M0 patients but 71% of the M+ patients exhibited an increased SAP. A corresponding cutoff point of 100 ng/ml for PSA showed that 19% of M0 patients and 71% of the M+ patients exhibited a value of >100 ng/ml. This resulted in a sensitivity and specificity of 71 and 100% of SAP and 71 and 81% for PSA, respectively.
SAP could become a useful marker in the evaluation of patients with newly diagnosed CaP as it provides additional information concerning the skeletal status of these patients.
研究前列腺特异性抗原（PSA）和骨碱性磷酸酶（SAP）作为分期标志物在鉴别有骨转移（M+）和无骨转移（M0）的前列腺癌（CaP）患者中的疗效。
73例未经治疗的CaP患者进入本研究。对患者进行分期后，将其分为3组：I组，有骨转移的CaP患者（n = 21）；II组，局部晚期无骨转移的CaP患者（n = 26），以及III组，临床局限性无骨转移的CaP患者（n = 26）。
M0患者中无一例SAP升高，但M+患者中有71%出现SAP升高。PSA的相应临界值为100 ng/ml，结果显示19%的M0患者和71%的M+患者PSA值>100 ng/ml。这使得SAP的敏感性和特异性分别为71%和100%，PSA的敏感性和特异性分别为71%和81%。
SAP可能成为评估新诊断CaP患者的有用标志物，因为它能提供有关这些患者骨骼状况的额外信息。
